V Gregorc

Summary

Affiliation: San Raffaele Scientific Institute
Country: Italy

Publications

  1. pmc Phase Ib study of NGR-hTNF, a selective vascular targeting agent, administered at low doses in combination with doxorubicin to patients with advanced solid tumours
    V Gregorc
    Department of Oncology, Istituto Scientifico San Raffaele, Via Olgettina, 60, Milan 20132, Italy
    Br J Cancer 101:219-24. 2009
  2. ncbi request reprint The clinical relevance of Bcl-2, Rb and p53 expression in advanced non-small cell lung cancer
    Vanesa Gregorc
    Division of Medical Oncology, Policlinico Monteluce, Via Brunamonti 51, Perugia 06122, Italy
    Lung Cancer 42:275-81. 2003
  3. ncbi request reprint Germline polymorphisms in EGFR and survival in patients with lung cancer receiving gefitinib
    V Gregorc
    Department of Oncology, Scientific Institute University Hospital San Raffaele, Milan, Italy
    Clin Pharmacol Ther 83:477-84. 2008
  4. ncbi request reprint Gefitinib in patients with brain metastases from non-small-cell lung cancer: a prospective trial
    G L Ceresoli
    Department of Oncology, Scientific Institute San Raffaele, Milan
    Ann Oncol 15:1042-7. 2004
  5. ncbi request reprint Feasibility of [18F]FDG-PET and coregistered CT on clinical target volume definition of advanced non-small cell lung cancer
    C Messa
    DNTB, School of Medicine, University of Milano Bicocca, Milan, Italy
    Q J Nucl Med Mol Imaging 49:259-66. 2005
  6. pmc Efficacy and tolerability of gefitinib in pretreated elderly patients with advanced non-small-cell lung cancer (NSCLC)
    F Cappuzzo
    Bellaria Hospital, Division of Medical Oncology, Via Altura 3, Bologna 40139, Italy
    Br J Cancer 90:82-6. 2004
  7. doi request reprint Plasma DNA, microsatellite alterations, and p53 tumor mutations are associated with disease-free survival in radically resected non-small cell lung cancer patients: a study of the perugia multidisciplinary team for thoracic oncology
    Vienna Ludovini
    Medical Oncology Division, Azienda Ospedale Perugia, Via Brunamonti 51, 06122 Perugia, Italy
    J Thorac Oncol 3:365-73. 2008
  8. ncbi request reprint Estrogen receptor (ER) and epidermal growth factor receptor (EGFR) as targets for dual lung cancer therapy: not just a case?
    Monica Giovannini
    J Thorac Oncol 3:684-5. 2008
  9. ncbi request reprint Biological markers and DNA flow cytometric analysis in radically resected patients with non-small cell lung cancer. A study of the Perugia Multidisciplinary Team for Thoracic Tumors
    Vienna Ludovini
    Medical Oncology, Azienda Ospedaliera, Perugia, Italy
    Tumori 94:398-405. 2008
  10. ncbi request reprint Endothelial growth factor receptor inhibition after radiotherapy
    Monica Giovannini
    Department of Medical Oncology, San Raffaele Scientific Institute, Milan, Italy
    J Thorac Oncol 2:662. 2007

Detail Information

Publications23

  1. pmc Phase Ib study of NGR-hTNF, a selective vascular targeting agent, administered at low doses in combination with doxorubicin to patients with advanced solid tumours
    V Gregorc
    Department of Oncology, Istituto Scientifico San Raffaele, Via Olgettina, 60, Milan 20132, Italy
    Br J Cancer 101:219-24. 2009
    ..Significant preclinical synergy was shown between low doses of NGR-TNF and doxorubicin...
  2. ncbi request reprint The clinical relevance of Bcl-2, Rb and p53 expression in advanced non-small cell lung cancer
    Vanesa Gregorc
    Division of Medical Oncology, Policlinico Monteluce, Via Brunamonti 51, Perugia 06122, Italy
    Lung Cancer 42:275-81. 2003
    ..The aim of this study was to evaluate the impact of Bcl-2, retinoblastoma (Rb) and p53 proteins on overall survival of 102 patients with locally advanced and metastatic NSCLC who underwent cisplatin-based chemotherapy...
  3. ncbi request reprint Germline polymorphisms in EGFR and survival in patients with lung cancer receiving gefitinib
    V Gregorc
    Department of Oncology, Scientific Institute University Hospital San Raffaele, Milan, Italy
    Clin Pharmacol Ther 83:477-84. 2008
    ..54; 95% confidence interval: 0.32-0.91; P=0.015). The results may help identify patients with NSCLC who can benefit from gefitinib treatment...
  4. ncbi request reprint Gefitinib in patients with brain metastases from non-small-cell lung cancer: a prospective trial
    G L Ceresoli
    Department of Oncology, Scientific Institute San Raffaele, Milan
    Ann Oncol 15:1042-7. 2004
    ..The aim of this study was to evaluate the activity and safety of gefitinib in NSCLC patients with brain metastases...
  5. ncbi request reprint Feasibility of [18F]FDG-PET and coregistered CT on clinical target volume definition of advanced non-small cell lung cancer
    C Messa
    DNTB, School of Medicine, University of Milano Bicocca, Milan, Italy
    Q J Nucl Med Mol Imaging 49:259-66. 2005
    ..To prospectively evaluate the impact of coregistered positron emission tomography (PET) and computed tomography (CT) in 3D conformal radiotherapy (3D-CRT) planning in patients with non-small lung cancer (NSCLC)...
  6. pmc Efficacy and tolerability of gefitinib in pretreated elderly patients with advanced non-small-cell lung cancer (NSCLC)
    F Cappuzzo
    Bellaria Hospital, Division of Medical Oncology, Via Altura 3, Bologna 40139, Italy
    Br J Cancer 90:82-6. 2004
    ..6%). Gefitinib is safe and well tolerated in elderly pretreated NSCLC patients. The disease-control rate achieved suggests that this drug could represent a valid option in the management of this unfavourable subgroup of patients...
  7. doi request reprint Plasma DNA, microsatellite alterations, and p53 tumor mutations are associated with disease-free survival in radically resected non-small cell lung cancer patients: a study of the perugia multidisciplinary team for thoracic oncology
    Vienna Ludovini
    Medical Oncology Division, Azienda Ospedale Perugia, Via Brunamonti 51, 06122 Perugia, Italy
    J Thorac Oncol 3:365-73. 2008
    ..This prospective study examined association between circulating plasma DNA, microsatellite alterations (MA), p53 mutations with time to relapse and survival in surgically treated non-small cell lung cancer (NSCLC) patients (pts)...
  8. ncbi request reprint Estrogen receptor (ER) and epidermal growth factor receptor (EGFR) as targets for dual lung cancer therapy: not just a case?
    Monica Giovannini
    J Thorac Oncol 3:684-5. 2008
  9. ncbi request reprint Biological markers and DNA flow cytometric analysis in radically resected patients with non-small cell lung cancer. A study of the Perugia Multidisciplinary Team for Thoracic Tumors
    Vienna Ludovini
    Medical Oncology, Azienda Ospedaliera, Perugia, Italy
    Tumori 94:398-405. 2008
    ....
  10. ncbi request reprint Endothelial growth factor receptor inhibition after radiotherapy
    Monica Giovannini
    Department of Medical Oncology, San Raffaele Scientific Institute, Milan, Italy
    J Thorac Oncol 2:662. 2007
  11. ncbi request reprint Prognostic value of circulating chromogranin A and soluble tumor necrosis factor receptors in advanced nonsmall cell lung cancer
    Vanesa Gregorc
    Department of Oncology, San Raffaele Scientific Institute, Milan, Italy
    Cancer 110:845-53. 2007
    ..The prognostic value of CgA and sTNF-Rs was investigated in advanced nonsmall cell lung cancer (NSCLC), a histologically heterogeneous group of tumors that may undergo neuroendocrine differentiation...
  12. ncbi request reprint Mass spectrometry to classify non-small-cell lung cancer patients for clinical outcome after treatment with epidermal growth factor receptor tyrosine kinase inhibitors: a multicohort cross-institutional study
    Fumiko Taguchi
    Department of Medicine, Vanderbilt Ingram Cancer Center, Nashville, TN 37232 6838, USA
    J Natl Cancer Inst 99:838-46. 2007
    ....
  13. ncbi request reprint Role of computed tomography and [18F] fluorodeoxyglucose positron emission tomography image fusion in conformal radiotherapy of non-small cell lung cancer: a comparison with standard techniques with and without elective nodal irradiation
    Giovanni Luca Ceresoli
    Department of Oncology and Hematology, Istituto Clinico Humanitas, Rozzano, Milan, Italy
    Tumori 93:88-96. 2007
    ....
  14. ncbi request reprint Pharmacogenetics of ABCG2 and adverse reactions to gefitinib
    George Cusatis
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA
    J Natl Cancer Inst 98:1739-42. 2006
    ..99). The finding suggests that patients with reduced ABCG2 activity due to a common genetic variant are at increased risk for substrate drug-induced diarrhea, with implications for optimizing treatment with such agents...
  15. ncbi request reprint Increased HER2 gene copy number is associated with response to gefitinib therapy in epidermal growth factor receptor-positive non-small-cell lung cancer patients
    Federico Cappuzzo
    University of Colorado Cancer Center, Department of Medicine and Pathology, Aurora, CO 80010, USA
    J Clin Oncol 23:5007-18. 2005
    ..Preclinical data indicate that HER2, a member of the EGFR family, could enhance TKI sensitivity...
  16. ncbi request reprint Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer
    Federico Cappuzzo
    University of Colorado Health Sciences Center and University of Colorado Cancer Center, Aurora, CO 80010, USA
    J Natl Cancer Inst 97:643-55. 2005
    ..We carried out a clinical study to compare the relationship between EGFR gene copy number, EGFR protein expression, EGFR mutations, and Akt activation status as predictive markers for gefitinib therapy in advanced NSCLC...
  17. ncbi request reprint Effects of gefitinib on serum epidermal growth factor receptor and HER2 in patients with advanced non-small cell lung cancer
    Vanesa Gregorc
    Department of Oncology, Scientific Institute University Hospital San Raffaele, Milan
    Clin Cancer Res 10:6006-12. 2004
    ....
  18. ncbi request reprint Vascular endothelial growth factor, p53, Rb, Bcl-2 expression and response to chemotherapy in advanced non-small cell lung cancer
    Vienna Ludovini
    Division of Medical Oncology, Policlinico Monteluce Hospital, Via Brunamonti 51, 06122 Perugia, Italy
    Lung Cancer 46:77-85. 2004
    ..28; p = 0.02). Our results suggest that VEGF is weakly correlated with regulators of apoptosis and has not been shown to be an independent predictive factor for resistance to cisplatin-based chemotherapy and prognostic for survival...
  19. ncbi request reprint Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer
    Federico Cappuzzo
    Department of Oncologic Sciences, Bellaria Maggiore Hospital, Bologna, Italy
    J Natl Cancer Inst 96:1133-41. 2004
    ....
  20. ncbi request reprint Phase II study of weekly paclitaxel as second-line therapy in patients with advanced non-small cell lung cancer
    Giovanni Luca Ceresoli
    Department of Oncology, Scientific Institute San Raffaele, Via Olgettina, 60 20132 Milan, Italy
    Lung Cancer 44:231-9. 2004
    ..Patients with PS 0-1, non-squamous histology and with no progression within 4 months of first line cisplatin-based chemotherapy seem more likely to benefit from this treatment...
  21. ncbi request reprint Gefitinib in pretreated non-small-cell lung cancer (NSCLC): analysis of efficacy and correlation with HER2 and epidermal growth factor receptor expression in locally advanced or metastatic NSCLC
    Federico Cappuzzo
    Bellaria Hospital, Division of Medical Oncology, Via Altura 3, 40139 Bologna, Italy
    J Clin Oncol 21:2658-63. 2003
    ..To evaluate the correlation between HER2 expression and gefitinib (ZD 1839, Iressa; AstraZeneca, London, United Kingdom) efficacy in terms of response rate, time to progression (TTP), and overall survival (OS) time...
  22. ncbi request reprint Gemcitabine and cisplatin as induction chemotherapy for patients with unresectable Stage IIIA-bulky N2 and Stage IIIB nonsmall cell lung carcinoma: an Italian Lung Cancer Project Observational Study
    Federico Cappuzzo
    Division of Medical Oncology, Bellaria Hospital, Bologna, Italy
    Cancer 98:128-34. 2003
    ..The objective of this trial was to evaluate the activity and safety of one of the newer platinum-based doublets as a neoadjuvant regimen in patients with unresectable Stage IIIA-bulky N2 and Stage IIIB nonsmall cell lung carcinoma (NSCLC)...
  23. ncbi request reprint Relevance of p53, bcl-2 and Rb expression on resistance to cisplatin-based chemotherapy in advanced non-small cell lung cancer
    Vanesa Gregorc
    Division of Medical Oncology, Policlinico Monteluce, Perugia, Italy
    Lung Cancer 39:41-8. 2003
    ..The relationships and interactions between p53, Rb and bcl-2 immunostaining, clinical parameters and response to cisplatin-based chemotherapy were evaluated in the present study...